Remegen Co Ltd (9995) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Remegen Co Ltd HK$23.55, price HK$77.10, upside -69.5%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Remegen Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$10.62 – HK$127.90 · fair‑value band HK$15.84 – HK$29.44 · the HK$77.10 price screens above the HK$23.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Remegen Co in your weekly email
Every Wednesday you see whether Remegen Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
Show more
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Stock analysis
Remegen Co Ltd (9995) currently trades at HK$77.10, while our model-based Fair Value estimate is HK$23.55, 69.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$68.55 per share, and 0 of the 17 models we run sit above the HK$77.10 price.
Bear case: the Economic Profit group reads lowest at HK$4.05, and 17 of the 17 models stay below the price. Evidence for this calculation is medium.
Scenario range: HK$15.84 (bear) to HK$29.44 (bull), the price of HK$77.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Remegen Co Ltd reported revenue of 3.2B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +22.8%/yr. Reported net income was 710M CNY in FY2025, compounding +26.6%/yr from FY2021.
Key figures
Market cap HK$43.4B (≈ $5.5B) · P/E ratio 6.0 · P/S ratio 1.31 · EPS (TTM) HK$11.80 · Dividend yield 0.2% · Net margin 21.9% · Return on equity 109% · Return on assets (EBIT) −12.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.
The share trades about 38% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −69%, 9995 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (HK$2.20 to HK$69.97). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$15.84Fair Value HK$23.55Bull HK$29.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$8.83 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+88.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+156.5%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+124.4%
’18
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+18.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.9%
Dividend (yield on the price)0.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2,424% → 5%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−69.5% · Below median
Profitability
Return on equity (TTM)109.1% · Top 25%
Return on assets39.0% · Top 25%
Net margin (TTM)72.7% · Top 25%
Operating margin (TTM)84.5% · Top 25%
Growth and dividend
Revenue growth808.6% · Top 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)6.0× · Cheapest 25%
P/B10.26× · Priciest 25%
P/S (TTM)4.63× · Pricier than median
EV/EBITDA7.1× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)90· sector 97
DIVIDEND (yield)3· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Remegen Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/9995
Frequently asked questions
Is Remegen Co Ltd (9995) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$23.55 versus a price of HK$77.10, about −69% upside (overvalued).
What is the fair value of 9995?
Our model-based fair value for Remegen Co Ltd is HK$23.55 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$77.10.
What is the quality score of 9995?
Remegen Co Ltd has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Remegen Co Ltd (9995)?
Our model-based price target is the fair value of HK$23.55 (as of Sep 27, 2026) from 17 valuation models. Cautious scenario HK$15.84, optimistic scenario HK$29.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Remegen Co Ltd stock forecast for 2026?
Our models put fair value at HK$23.55, about −69% upside versus a price of HK$77.10 (overvalued). Cautious scenario HK$15.84, optimistic scenario HK$29.44. The calculation is refreshed regularly with new filings.
What is the revenue of Remegen Co Ltd (9995)?
Remegen Co Ltd reported trailing-twelve-month revenue of about 8.0B CNY (latest available figure, as of Sep 27, 2026).
Does Remegen Co Ltd pay a dividend?
Remegen Co Ltd currently shows a dividend yield of about 0.16% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Remegen Co Ltd (9995)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Remegen Co Ltd it is HK$23.55 per share (as of Sep 27, 2026), against a price of HK$77.10. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Remegen Co Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 9995 trades above its calculated fair value: price HK$77.10, fair value HK$23.55, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9995?
No. The price is what the market pays today (HK$77.10); the fair value is what the company's own numbers justify (HK$23.55). For Remegen Co Ltd the two are HK$53.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Remegen Co Ltd worth?
The market values Remegen Co Ltd at about HK$43.4B (market capitalisation, as of Sep 27, 2026). Per share that is HK$77.10; our models calculate a fair value of HK$23.55 per share.
What do the bullish and bearish scenarios say about 9995?
Our models span a range for Remegen Co Ltd: cautious scenario HK$15.84, base HK$23.55, optimistic HK$29.44 per share (as of Sep 27, 2026, price HK$77.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9995?
Remegen Co Ltd trades at a price-to-earnings ratio of 6.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$23.55 is built from several models across several years. Other multiples: P/B 10.3, P/S 4.6, EV/EBITDA 7.1.
How solid is the balance sheet of Remegen Co Ltd (9995)?
Balance-sheet figures for Remegen Co Ltd (as of Sep 27, 2026): return on equity 109.1%, debt of 0.20 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 9995 from its 52-week high?
Remegen Co Ltd trades at HK$77.10, about 38% below its 52-week high of HK$125.00 and 16% above the low of HK$66.75 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$23.55 is for.
Which stocks are comparable to Remegen Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Remegen Co Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$77.10, calculated fair value HK$23.55 (−69%), Quality Score 69/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9995 calculated?
We run Remegen Co Ltd through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$23.55, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Remegen Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Remegen Co Ltd (9995)?
The closing price on Sep 30, 2026 was HK$77.10. Our model-based fair value is HK$23.55, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Remegen Co Ltd right now?
The price sits above even our optimistic bull case (HK$29.44). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$15.84 to HK$29.44) leaves room in how you read the outcome.
Key figures of Remegen Co Ltd
How large is the market capitalisation of Remegen Co Ltd (9995)?
The market capitalisation of Remegen Co Ltd is HK$43.4B (≈ $5.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Remegen Co Ltd (9995)?
The price-to-sales ratio of Remegen Co Ltd is 1.31 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Remegen Co Ltd (9995)?
Earnings per share at Remegen Co Ltd are HK$11.80 (price ÷ EPS = P/E 6.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Remegen Co Ltd (9995)?
The dividend yield of Remegen Co Ltd is 0.2% (payout 1.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Remegen Co Ltd (9995)?
The net margin of Remegen Co Ltd is 21.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Remegen Co Ltd (9995)?
The return on equity (ROE) of Remegen Co Ltd is 109% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Remegen Co Ltd (9995)?
On an EBIT basis the return on assets of Remegen Co Ltd is −12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Remegen Co Ltd (9995)?
The operating margin of Remegen Co Ltd is 84.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Remegen Co Ltd (9995)?
Revenue at Remegen Co Ltd is growing +809% versus a year earlier (3y avg +61.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Remegen Co Ltd (9995) generate?
The free cash flow of Remegen Co Ltd is −140M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Remegen Co Ltd (9995) carry?
The net debt of Remegen Co Ltd is 1.0B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Remegen Co Ltd in the live analysis
One click puts Remegen Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 27, 2026